PALV-08 is a multicenter, open-label treatment (OLT) study enrolling adults with Pachyonychia Congenita (PC) with genotyped keratin mutations KRT6A, KRT6B, KRT6C or KRT16 who were previously enrolled in the PALV-05 (VAPAUS) trial.

The purpose of this OLT study is to investigate the safety of long term exposure and pharmacokinetics (PK) of QTORIN rapamycin 3.9% anhydrous gel or "PTX-022".

Key Inclusion Criteria:

• Completed the PALV-05 (VAPAUS) study
• Agree to contraceptive use

Key Exclusion Criteria:

• Females who are pregnant or breastfeeding
• Concomitant use of sirolimus or any sirolimus-containing medications (systemic or topical)
• Any significant concurrent condition that could adversely affect participation and/or the assessment of the safety and efficacy in the study
• Prior or planned treatment, including surgery or other medically necessary intervention deemed by the investigator that could adversely affect participation and/or the assessment of the safety and efficacy in the study